Table 1.
Baseline characteristics of all patients (N = 157).
| N | % | |
|---|---|---|
| Age, years | ||
| < 65 | 116 | 73.9 |
| ≥ 65 | 41 | 26.1 |
| Sex | ||
| Male | 85 | 54.1 |
| Female | 72 | 45.9 |
| Primary site | ||
| Right colon | 42 | 26.8 |
| Left colon | 115 | 73.2 |
| Histology | ||
| W/D adenocarcinoma* | 10 | 6.4 |
| M/D adenocarcinoma* | 118 | 75.2 |
| P/D adenocarcinoma* | 29 | 18.5 |
| Site of metastasis | ||
| Liver | 91 | 58.0 |
| Lung | 62 | 39.5 |
| Lymph node | 50 | 31.8 |
| Peritoneum | 33 | 21.0 |
| Others* | 20 | 12.7 |
| Sum of metastasis | ||
| 1 organ metastasis, excluding peritoneum | 65 | 41.4 |
| 2 or more organ metastasis, excluding peritoneum | 59 | 37.6 |
| Any number of organs plus peritoneum | 33 | 21.0 |
| RAS mutation | ||
| Wild | 74 | 47.1 |
| Mutant | 83 | 52.9 |
| BRAF mutation | ||
| Wild | 142 | 90.4 |
| Mutant | 8 | 5.1 |
| Unknown | 7 | 4.5 |
| Previous systemic treatment lines | ||
| 2 | 85 | 54.1 |
| ≥ 3 | 72 | 45.9 |
| Time from first diagnosis of metastatic disease to treatment | ||
| < 24 months | 74 | 47.1 |
| ≥ 24 months | 83 | 52.9 |
| Previous targeted agents | ||
| RAS/RAF wild-type (n = 70) | ||
| Prior bevacizumab and cetuximab | 19 | 12.1 |
| Prior bevacizumab | 1 | 0.1 |
| Prior cetuximab | 32 | 20.4 |
| RAS or RAF mutated (n = 87) | ||
| Prior bevacizumab | 36 | 22.9 |
| Previous chemotherapy | ||
| Fluoropyrimidine | ||
| Refractory | 157 | 100 |
| Intolerant | 0 | 0 |
| Oxaliplatin | ||
| Refractory | 149 | 96.1 |
| Intolerant | 4 | 2.5 |
| Irinotecan | ||
| Refractory | 156 | 99.4 |
| Intolerant | 1 | 0.6 |
*Ovary 4%, bone 8%, etc., 4%.
W/D well differentiated, M/D moderately differentiated, P/D poorly differentiated, MSI microsatellite instability, MSS microsatellite stable. VEGF vascular endothelial growth factor, EGFR epidermal growth factor receptor.
FOLFOX; FU, leucovorin, and oxaliplatin, FOLFIRI; fluorouracil (FU), leucovorin, and irinotecan.